டெங்கு தடுப்பூசி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Takeda and IDT Support Manufacturing of Johnson & Johnson’s COVID-19 Vaccine Monday, March 15, 2021 5:35PM IST (12:05PM GMT) − Takeda will make manufacturing capacity available at IDT’s facilities in Germany   Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced a mutual agreement with IDT Biologika GmbH (“IDT”), a contract development and manufacturing organization, to utilize capacity at IDT previously reserved for Takeda’s dengue vaccine candidate (TAK-003) to manufacture the single-shot COVID-19 vaccine developed by the Janssen Pharmaceutical Companies of Johnson & Johnson. At the end of a three-month period, the capacity will be returned to Takeda to resume critical manufacturing for the planned launch of its dengue vaccine, subject to regulatory approvals.

United statesRachel wieseKazumi kobayashiBiologika gmbRajeev venkayyaPlasma allianceTakeda pharmaceutical company limitedGerman centerJanssen pharmaceutical companies of johnsonCare allianceTakeda pharmaceutical companyExchange commissionCovid rd allianceGovernment of japan ministry health labourVaccine researchPharmaceutical company limited